{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-001189","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.673200+00:00","generated_at":"2026-05-16T11:19:29.989632+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Globus Medical reports record Q4 sales $823M (+25% YoY); FY2026 guidance $3.18-3.22B","bullets":["Preliminary Q4 2025 sales ~$823.2M, +25.2% YoY; full year sales ~$2.936B, +16.5% YoY.","Base business (ex-Nevro) Q4 revenue $723.3M, +10.0% YoY, led by US Spine.","Enabling Technologies delivered best quarterly revenue performance to date.","FY2026 revenue guidance $3.18B-$3.22B; non-GAAP EPS guidance $4.30-$4.40.","Final Q4/FY2025 results expected on February 24, 2026 after market close."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-001189","json":"https://secwatch.observer/filing/0001628280-26-001189.json","markdown":"https://secwatch.observer/filing/0001628280-26-001189.md","text":"https://secwatch.observer/filing/0001628280-26-001189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026001189/0001628280-26-001189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000162828026001189/gmed-20260107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:19:29.989632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}